Puerto Rican pharmaceuticals are key to US biotech domination – otherwise dependence on foreign pharmaceutical supplies creates security risks.
Garcia and Beverly 21 (Lynne Chandler Garcia is an Assistant Professor of Political Science at the United States Air Force Academy. Michael Beverley is the Vice-Chair and Co-Founder of OneMedical Grouph; “Reinvigorating Puerto Rico’s Pharmaceutical Industry: A U.S. Security Imperative”; Centro Journal; Vol. 33 Issue 2; Summer 2021; https://web.s.ebscohost.com/ehost/detail/detail?vid=0&sid=19ad5725-03b5-438b-b2fa-185df1e64773%40redis&bdata=JnNpdGU9ZWhvc3QtbGl2ZSZzY29wZT1zaXRl#AN=152480710&db=a9h)
Puerto Rico’s lack of representation in Congress is a distinct disadvantage. State legislators may not support programs such as more favorable tax treatment through the repeal of GILTI if it has a negative impact on their own constituents. Puerto Rico’s unequal representation means that the territory must rely on the diaspora of Puerto Ricans living on the mainland. Approximately 5.4 million Puerto Ricans live on the mainland, with the largest concentrations in New York, Florida, and New Jersey. Harnessing the political capital of these citizens may be critical in swaying Congressional members to vote for legislation that favors the territory. For this reason, the recent collaboration between Resident Commissioner Jenniffer González Colón and Florida Senator Marco Rubio is sound strategy. Rubio can harness the strong Puerto Rican constituency in Florida while solving a broader U.S. security concern. Further, seeking support for economically distressed zones in general has a wider appeal than legislation aimed just at Puerto Rico. Thus, this type of legislation may have a stronger chance of being supported in Congress than bills aimed at eliminating the GILTI tax. Because solutions to the U.S.’s security issue involving dependency upon foreign pharmaceuticals and solutions to Puerto Rico’s economic crisis ultimately rest on political solutions, Puerto Rico will need to harness enough political capital to secure legislation that puts the Island at the center of reshoring efforts. At the same time, because Puerto Rico is ready to increase pharmaceutical production, almost any legislation to reshore Reinvigorating Puerto Rico’s Pharmaceutical Industry: A U.S. Security Imperative • Lynne Chandler Garcia and Michael Beverley 87 production will benefit the Island. Thus, Puerto Rico stands to benefit from any number of legislative initiatives currently in Congress. Concluding Thoughts Although this national security issue had been growing for decades, the COVID pandemic exposed the U.S’s critical dependency on foreign nations for prescription drugs and medical devices. White House Office of Trade and Manufacturing Director Peter Navarro commented, “If this crisis has taught us anything across party lines is that we do indeed need to bring home the pharmaceutical supply chain, that it is not just a public health issue, but a national security issue and an economic security issue” (Doyle 2020). Heading into the 2020 presidential elections, the fate of legislation and presidential plans for reshoring was precarious. On the campaign trail, President Trump boasted of his executive order to import less expensive pharmaceuticals from Canada. This was a step in the wrong direction because although it might reduce prices, it does not alleviate U.S. dependency on foreign countries. Candidate Joe Biden’s campaign promises included efforts to bring supply chains back from China, but his plan for Puerto Rico did not include a strong effort to bolster manufacturing. In recent months neither President Trump nor President-elect Biden has publically discussed the need to reshore the pharmaceutical industry. Further, the legislation discussed has stalled within Congress, and there is little indication that any movement on these bills is forthcoming. With COVID vaccinations rolling out to the public, a sense of complacency could set in, and there is a danger that the issue might fall off the political agenda as new security challenges take center stage. It remains to be seen if President-Elect Biden and the Democrat-controlled Congress will prioritize the security problems caused by foreign manufacture of pharmaceuticals and medical devices. The other unknown is if the citizens of the United States will be willing to bear the costs of reshoring in order to secure supply lines. Despite the urgency of this issue, the cost of reshoring will be extremely expensive. Higher wages, more expensive land, stricter quality and environmental standards, and increased government incentives all add up to much higher costs of production for American-made pharmaceutical products. These costs will likely be passed on to consumers in the form of higher prices. At the height of the 88 centro journal • volume xxxiii • number ii • summer 2021 COVID pandemic, consumers may be willing to pay more for American-made products. However, memories are short, and once fervor over the pandemic quiets down, consumers may be reticent to pay higher prices. The national security crisis caused by U.S. dependency on foreign pharmaceuticals must be solved, and Puerto Rico’s capacity to help solve this problem should be capitalized. Legislators must act while public sentiment is in favor of new solutions.